Skip header and navigation

14 records – page 1 of 1.

Bowel preparation for chronic kidney disease before colonoscopy

https://libcat.nshealth.ca/en/permalink/chpams35387
Nova Scotia Health Authority. Renal Program, Nova Scotia Health Authority. Pharmacy Services. Halifax, NS: Nova Scotia Health Authority , 2020.
Pamphlet Number
1475
Available Online
View Pamphlet
This pamphlet describes how to get ready for a colonoscopy if you have chronic kidney disease. Steps to prepare solutions on the day before your colonoscopy are listed. The day before your procedure and on the day of the test you should drink only clear liquids, and a suggested list is included. Remember not to eat any food or drink milk, or other liquids that are not clear, on the day before your colonoscopy or on the day of the test.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Renal Program
Nova Scotia Health Authority. Pharmacy Services
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2020
Format
Pamphlet
Language
English
Physical Description
1 electronic document (5 p.) : digital, PDF file
Subjects (MeSH)
Cathartics
Colonoscopy
Renal Insufficiency, Chronic
Subjects (LCSH)
Laxatives
Colonoscopy
Chronic renal failure
Specialty
Medications
Nephrology
Abstract
This pamphlet describes how to get ready for a colonoscopy if you have chronic kidney disease. Steps to prepare solutions on the day before your colonoscopy are listed. The day before your procedure and on the day of the test you should drink only clear liquids, and a suggested list is included. Remember not to eat any food or drink milk, or other liquids that are not clear, on the day before your colonoscopy or on the day of the test.
Responsibility
Prepared by: NSHA Renal Program Educators and Pharmacists
Pamphlet Number
1475
Less detail

Cinacalcet (Sensipar) to treat secondary hyperparathyroidism in chronic kidney disease (CKD)

https://libcat.nshealth.ca/en/permalink/chpams35371
Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2019.
Pamphlet Number
1465
Available Online
View Pamphlet
Secondary hyperparathyroidism is a condition that can be caused by kidney disease. It happens when your kidneys can’t filter out waste products the right way. This leads to too much parathyroid hormone in your blood. Cinacalcet (sin-a-KAL-cet) is a medicine used to lower the level of parathyroid hormone in your blood. This will help to balance your calcium and phosphorous levels. Sensipar® is a brand name for cinacalcet. How to take this medicine and what side effects to watch for are reviewed.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Renal Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2019
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([4] p.) : digital, PDF file
Subjects (MeSH)
Cinacalcet
Renal Insufficiency, Chronic - drug therapy
Hyperparathyroidism, Secondary - drug therapy
Subjects (LCSH)
Chronic renal failure
Hyperparathyroidism
Kidneys--Diseases--Treatment
Abstract
Secondary hyperparathyroidism is a condition that can be caused by kidney disease. It happens when your kidneys can’t filter out waste products the right way. This leads to too much parathyroid hormone in your blood. Cinacalcet (sin-a-KAL-cet) is a medicine used to lower the level of parathyroid hormone in your blood. This will help to balance your calcium and phosphorous levels. Sensipar® is a brand name for cinacalcet. How to take this medicine and what side effects to watch for are reviewed.
Notes
Previous title: Sensipar (Cinacalcet) to treat secondary hyperparathyroidism in chronic kidney disease
Responsibility
Prepared by: NSHA Renal Program
Pamphlet Number
1465
Less detail

Erythropoieis-stimulating agents (ESAs) for chronic kidney disease (CKD) : with active cancer or a history of cancer or stroke

https://libcat.nshealth.ca/en/permalink/chpams37446
Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2021.
Pamphlet Number
2217
Available Online
View Pamphlet
Erythropoiesis-stimulating agents (ESAs) are a group of medicines that help take the place of a hormone called erythropoietin (EPO). People with chronic kidney disease (CKD) may not have enough EPO coming from their kidneys to tell their body to make more red blood cells. This can cause their red blood cell count to drop and anemia (not enough red blood cells or hemoglobin in the blood) to develop. If you have CKD and active cancer or a history of cancer of stroke, it is important to carefully …
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Renal Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2021
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([2] p.) : digital, PDF file
Subjects (MeSH)
Renal insufficiency, chronic - complications
Anemia - drug therapy
Hematinics - therapeutic use
Neoplasms
Stroke
Subjects (LCSH)
Chronic renal failure--Complications
Hematopoietic growth factors
Renal anemia--Chemotherapy
Cancer
Cerebrovascular disease
Abstract
Erythropoiesis-stimulating agents (ESAs) are a group of medicines that help take the place of a hormone called erythropoietin (EPO). People with chronic kidney disease (CKD) may not have enough EPO coming from their kidneys to tell their body to make more red blood cells. This can cause their red blood cell count to drop and anemia (not enough red blood cells or hemoglobin in the blood) to develop. If you have CKD and active cancer or a history of cancer of stroke, it is important to carefully consider the risks and benefits of ESAs. The risks and benefits of ESAs are listed. Your health care team will talk with you about the risks and benefits of ESAs and other factors to consider when making the decision to take ESAs.
Responsibility
Prepared by: Renal Program
Pamphlet Number
2217
Less detail

Erythropoiesis-stimulating agent (ESA) therapy and chronic kidney disease (CKD)

https://libcat.nshealth.ca/en/permalink/chpams35406
Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2020.
Pamphlet Number
1493
Available Online
View Pamphlet
Erythropoiesis-stimulating agents (ESAs) are a group of medicines that help take the place of a hormone called erythropoietin (EPO). People with chronic kidney disease (CKD) may not have enough EPO coming from their kidneys to tell their body to make more red blood cells. This can cause their red blood cell count to drop and anemia (not enough red blood cells or hemoglobin in the blood) to develop. How to take and store this medicine and possible side effects to watch for are reviewed.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Renal Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2020
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([4] p.) : digital, PDF file
Subjects (MeSH)
Renal insufficiency, chronic - complications
Anemia - drug therapy
Hematinics - therapeutic use
Subjects (LCSH)
Chronic renal failure--Complications
Hematopoietic growth factors
Renal anemia--Chemotherapy
Abstract
Erythropoiesis-stimulating agents (ESAs) are a group of medicines that help take the place of a hormone called erythropoietin (EPO). People with chronic kidney disease (CKD) may not have enough EPO coming from their kidneys to tell their body to make more red blood cells. This can cause their red blood cell count to drop and anemia (not enough red blood cells or hemoglobin in the blood) to develop. How to take and store this medicine and possible side effects to watch for are reviewed.
Responsibility
Prepared by: Renal Program
Pamphlet Number
1493
Less detail

Fer injectable et insuffisance rénale chronique (IRC)

https://libcat.nshealth.ca/en/permalink/chpams37473
Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2020.
Pamphlet Number
2161
Available Online
View Pamphlet
Si votre corps manque d’oxygène en raison d’une carence en fer, il se peut que vous soyez fatigué ou essoufflé. On appelle cela l’anémie ferriprive. Beaucoup de patients atteints d’insuffisance rénale chronique (IRC) ou dialysés souffrent d’anémie, car ils n’ont pas assez de globules rouges, et le corps a besoin de fer pour les fabriquer. Prendre du fer par injection permet donc au corps d’avoir suffisamment de fer pour fabriquer de l’hémoglobine, c’est-à-dire la protéine qui transporte l’oxygè…
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Renal Program
Alternate Title
Injectable iron and chronic kidney disease (CKD)
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2020
Format
Pamphlet
Language
French
Physical Description
1 electronic document ([4] p.) : digital, PDF file
Subjects (MeSH)
Renal Dialysis
Iron - therapeutic use
Kidney Diseases
Anemia, Iron-Deficiency
Subjects (LCSH)
Hemodialysis
Chronic renal failure--Complications
Iron deficiency anemia
Abstract
Si votre corps manque d’oxygène en raison d’une carence en fer, il se peut que vous soyez fatigué ou essoufflé. On appelle cela l’anémie ferriprive. Beaucoup de patients atteints d’insuffisance rénale chronique (IRC) ou dialysés souffrent d’anémie, car ils n’ont pas assez de globules rouges, et le corps a besoin de fer pour les fabriquer. Prendre du fer par injection permet donc au corps d’avoir suffisamment de fer pour fabriquer de l’hémoglobine, c’est-à-dire la protéine qui transporte l’oxygène. Ce dépliant explique comment prendre du fer injectable, ses effets possibles et comment le conserver.
This pamphlet is a French translation of the English pamphlet 1495, "Injectable Iron and Chronic Kidney Disease (CKD)". If your body is not getting enough oxygen due to lack of iron, you may feel tired or short of breath. This is called iron deficiency anemia. Many patients with chronic kidney disease (CKD), or who are on dialysis, have anemia because their red blood cells are low. The body needs iron to help make new red blood cells. Getting iron injections can help make sure that you have enough iron in your body to make the oxygen-carrying part (hemoglobin) of your red blood cells. This pamphlet explains how to take injectable iron, side effects to watch for, and instructions on how to store the medication.
Notes
Previous title: Injectable iron sucrose and chronic kidney disease
Responsibility
Prepared by: NSHA Renal Program
Pamphlet Number
2161
Less detail

Injectable iron and chronic kidney disease (CKD)

https://libcat.nshealth.ca/en/permalink/chpams35408
Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2020.
Pamphlet Number
1495
Available Online
View Pamphlet
If your body is not getting enough oxygen due to lack of iron, you may feel tired or short of breath. This is called iron deficiency anemia. Many patients with chronic kidney disease (CKD), or who are on dialysis, have anemia because their red blood cells are low. The body needs iron to help make new red blood cells. Getting iron injections can help make sure that you have enough iron in your body to make the oxygen-carrying part (hemoglobin) of your red blood cells. This pamphlet explains how …
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Renal Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2020
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([4] p.) : digital, PDF file
Subjects (MeSH)
Renal Dialysis
Iron - therapeutic use
Kidney Diseases
Anemia, Iron-Deficiency
Subjects (LCSH)
Hemodialysis
Chronic renal failure--Complications
Iron deficiency anemia
Abstract
If your body is not getting enough oxygen due to lack of iron, you may feel tired or short of breath. This is called iron deficiency anemia. Many patients with chronic kidney disease (CKD), or who are on dialysis, have anemia because their red blood cells are low. The body needs iron to help make new red blood cells. Getting iron injections can help make sure that you have enough iron in your body to make the oxygen-carrying part (hemoglobin) of your red blood cells. This pamphlet explains how to take injectable iron, side effects to watch for, and instructions on how to store the medication. The French version of this pamphlet 2161, "Fer injectable et insuffisance rénale chronique (IRC)," is also available.
Notes
Previous title: Injectable iron sucrose and chronic kidney disease
Responsibility
Prepared by: NSHA Renal Program
Pamphlet Number
1495
Less detail

Lanthanum (Fosrenol) and chronic kidney disease (CKD)

https://libcat.nshealth.ca/en/permalink/chpams35370
Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2019.
Pamphlet Number
1466
Available Online
View Pamphlet
Lanthanum (LAN-tha-num) is a medicine used to treat high levels of phosphorus (a mineral that builds strong bones and teeth) in the body. Lanthanum binds (attaches) to the phosphorus in the foods you eat and stops your body from taking it in. People with kidney disease are less able to remove phosphorus from the body. When phosphorus levels in the blood get too high, it pushes calcium out from your bones. This makes them weaker. Hemodialysis can remove some of the extra phosphorus, but medicin…
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Renal Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2019
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([4] p.) : digital, PDF file
Subjects (MeSH)
Renal Insufficiency, Chronic - drug therapy
Renal Dialysis
Lanthanum
Subjects (LCSH)
Chronic renal failure
Kidneys--Diseases--Treatment
Hemodialysis
Abstract
Lanthanum (LAN-tha-num) is a medicine used to treat high levels of phosphorus (a mineral that builds strong bones and teeth) in the body. Lanthanum binds (attaches) to the phosphorus in the foods you eat and stops your body from taking it in. People with kidney disease are less able to remove phosphorus from the body. When phosphorus levels in the blood get too high, it pushes calcium out from your bones. This makes them weaker. Hemodialysis can remove some of the extra phosphorus, but medicines such as lanthanam are often needed to help remove more. How to take the medicine and what side effects to watch for are reviewed. Fosrenol® is a brand name for lanthanum.
Notes
Previous title: Fosrenol (Lanthanum) and hemodialysis
Responsibility
Prepared by: NSHA Renal Program
Pamphlet Number
1466
Less detail

Management of chronic kidney disease : a clinician's guide

https://libcat.nshealth.ca/en/permalink/provcat33898
Mustafa Arici, editor. --Heidelberg: Springer , c2014.
Available Online
View e-Book
Location
Online
This book presents a comprehensive and instructive management plan for physicians who care for CKD patients. Basic aspects of CKD, clinical assessment, evaluation and management of risk factors, cardiovascular disease in the context of CKD, assessment and management of CKD complications, special circumstances in CKD patients, and the path to renal replacement therapy are all thoroughly covered. Diagnostic and therapeutic approaches are presented according to the latest staging system for CKD, w…
Available Online
View e-Book
Other Authors
Arici, Mustafa
Responsibility
Mustafa Arici, editor
Alternate Title
Managing chronic kidney disease
Place of Publication
Heidelberg
Publisher
Springer
Date of Publication
c2014
Physical Description
1 online resource (xvii, 513 pages)
ISBN
9783642546372 (electronic bk.)
9783642546365
Subjects (MeSH)
Renal Insufficiency, Chronic - therapy
Subjects (LCSH)
Chronic renal failure - Treatment
Abstract
This book presents a comprehensive and instructive management plan for physicians who care for CKD patients. Basic aspects of CKD, clinical assessment, evaluation and management of risk factors, cardiovascular disease in the context of CKD, assessment and management of CKD complications, special circumstances in CKD patients, and the path to renal replacement therapy are all thoroughly covered. Diagnostic and therapeutic approaches are presented according to the latest staging system for CKD, with patient care being discussed separately for each disease stage. The proposed management plan is both 'best available evidence based' and 'practice based'. The book also recognizes the needs of busy clinicians by including helpful boxes summarizing the evidence on diagnostic and therapeutic issues and practice pearls based on guidelines.
Contents
CKD: Basics and Clinical Assessment -- CKD Risk Factors: Assessment and Management -- CKD and Cardiovascular Diseases -- CKD Complications: Assessment and Management -- CKD: Special Conditions -- CKD: Final Path to Renal Replacement Therapy.
Format
e-Book
Location
Online
Less detail

One-Alpha® (alfacalcidol) and hemodialysis

https://libcat.nshealth.ca/en/permalink/chpams36672
Nova Scotia Health Authority. Pharmacy Services, Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2020.
Pamphlet Number
1470
Available Online
View Pamphlet
One-Alpha® is a medicine that contains the active ingredient alfacalcidol, which is a form of vitamin D. The liver changes alfacalcidol to calcitriol, which is a form of vitamin D that can be used by the body. It acts as a hormone in your body to control the levels of calcium and phosphate, which are needed to build healthy bone. People with kidney disease cannot change enough vitamin D into calcitriol. We get vitamin D from sunlight, and from eating oily fish and milk products. This can cause …
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Pharmacy Services
Nova Scotia Health Authority. Renal Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2020
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([4] p.) : digital, PDF file
Subjects (MeSH)
Renal Insufficiency, Chronic - drug therapy
Renal Dialysis
Subjects (LCSH)
Chronic renal failure
Kidneys--Diseases--Treatment
Hemodialysis
Abstract
One-Alpha® is a medicine that contains the active ingredient alfacalcidol, which is a form of vitamin D. The liver changes alfacalcidol to calcitriol, which is a form of vitamin D that can be used by the body. It acts as a hormone in your body to control the levels of calcium and phosphate, which are needed to build healthy bone. People with kidney disease cannot change enough vitamin D into calcitriol. We get vitamin D from sunlight, and from eating oily fish and milk products. This can cause low levels of calcium in the blood and bone problems. This medicine skips the step done by the kidneys and increases the amount of vitamin D in your body that can be used. How to take the medicine and what side effects to watch for are reviewed. One-Alpha® is a brand name for alfacalcidol.
Responsibility
Prepared by: Renal Pharmacy Team, NSHA Renal Program
Pamphlet Number
1470
Less detail

Oral irons and chronic kidney disease (CKD)

https://libcat.nshealth.ca/en/permalink/chpams35375
Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2020.
Pamphlet Number
1469
Available Online
View Pamphlet
Your red blood cells need iron to help carry oxygen through your body. Many people with chronic kidney disease (CKD) have anemia (not enough red blood cells or hemoglobin in the blood). Oral irons, such as ferrous sulfate, ferrous gluconate, ferrous fumarate, and FeraMAX® 150, will give you enough iron to make make hemoglobin. This will make sure your body gets enough oxygen. How to take and store these medicines, and what side effects to watch for are reviewed.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Renal Program
Alternate Title
Oral irons and CKD
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2020
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([4] p.) : digital, PDF file
Subjects (MeSH)
Renal insufficiency, chronic - complications
Renal Insufficiency, Chronic - drug therapy
Anemia, Iron-Deficiency - drug therapy
Subjects (LCSH)
Chronic renal failure--Complications
Iron deficiency anemia
Renal pharmacology
Abstract
Your red blood cells need iron to help carry oxygen through your body. Many people with chronic kidney disease (CKD) have anemia (not enough red blood cells or hemoglobin in the blood). Oral irons, such as ferrous sulfate, ferrous gluconate, ferrous fumarate, and FeraMAX® 150, will give you enough iron to make make hemoglobin. This will make sure your body gets enough oxygen. How to take and store these medicines, and what side effects to watch for are reviewed.
Responsibility
Prepared by: Renal Program
Pamphlet Number
1469
Less detail

Over-the-counter medications & chronic kidney disease

https://libcat.nshealth.ca/en/permalink/chpams35643
Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2019.
Pamphlet Number
1636
Available Online
View Pamphlet
If you have chronic kidney disease, you need to be aware of certain over-the-counter medications that are your best choices and those that could cause unpleasant side effects. This pamphlet lists common ailments (e.g., cough and cold, fever or pain, allergies, upset stomach or heartburn, nausea or vomiting, diarrhea, constipation) and over-the-counter medications that are your best choices, their costs, and medications to stay away from. It also lists your best choices for multivitamins, creams…
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Renal Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2019
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([6] p.) : digital, PDF file
Subjects (MeSH)
Nonprescription Drugs
Renal Insufficiency, Chronic - drug therapy
Subjects (LCSH)
Drugs, Nonprescription
Chronic renal failure
Specialty
Medications
Abstract
If you have chronic kidney disease, you need to be aware of certain over-the-counter medications that are your best choices and those that could cause unpleasant side effects. This pamphlet lists common ailments (e.g., cough and cold, fever or pain, allergies, upset stomach or heartburn, nausea or vomiting, diarrhea, constipation) and over-the-counter medications that are your best choices, their costs, and medications to stay away from. It also lists your best choices for multivitamins, creams and ointments, and gives information on why herbal products are not recommended.
Responsibility
Prepared by: Renal Program
Pamphlet Number
1636
Less detail

Rocaltrol® (calcitriol) and hemodialysis

https://libcat.nshealth.ca/en/permalink/chpams36671
Nova Scotia Health Authority. Pharmacy Services, Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2020.
Pamphlet Number
1468
Available Online
View Pamphlet
Rocaltrol® is a medicine that contains the active ingredient calcitriol, which is a form of vitamin D that can be used by the body. It acts as a hormone in your body to control the levels of calcium and phosphate, which are needed to build healthy bone. People with kidney disease cannot change enough vitamin D into calcitriol. We get vitamin D from sunlight, and from eating oily fish and milk products. This can cause low levels of calcium in the blood and bone problems. This medicine skips the …
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Pharmacy Services
Nova Scotia Health Authority. Renal Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2020
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([4] p.) : digital, PDF file
Subjects (MeSH)
Renal Insufficiency, Chronic - drug therapy
Renal Dialysis
Calcitriol
Subjects (LCSH)
Chronic renal failure
Kidneys--Diseases--Treatment
Hemodialysis
Abstract
Rocaltrol® is a medicine that contains the active ingredient calcitriol, which is a form of vitamin D that can be used by the body. It acts as a hormone in your body to control the levels of calcium and phosphate, which are needed to build healthy bone. People with kidney disease cannot change enough vitamin D into calcitriol. We get vitamin D from sunlight, and from eating oily fish and milk products. This can cause low levels of calcium in the blood and bone problems. This medicine skips the step done by the kidneys and increases the amount of vitamin D in your body that can be used. How to take the medicine and what side effects to watch for are reviewed. Rocaltrol® is a brand name for calcitriol.
Responsibility
Prepared by: Renal Pharmacy Team, NSHA Renal Program
Pamphlet Number
1468
Less detail

Sevelamer (Renagel) and chronic kidney disease (CKD)

https://libcat.nshealth.ca/en/permalink/chpams35372
Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2019.
Pamphlet Number
1464
Available Online
View Pamphlet
Sevelamer (se-VEL-a-mer) is a medicine used to treat high levels of phosphorus (a mineral that builds strong bones and teeth) in the body. People with kidney disease are less able to remove phosphorus from their body. When phosphorus levels in the blood get too high, it pushes calcium out from your bones. Hemodialysis can remove some of the extra phosphorus, but medicines such as sevelamer are often needed to help remove more. How to take sevelamer and what side effects to watch for are reviewe…
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Renal Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2019
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([4] p.) : digital, PDF file
Subjects (MeSH)
Sevelamer
Renal Insufficiency, Chronic - drug therapy
Renal Dialysis
Subjects (LCSH)
Hemodialysis
Chronic renal failure
Kidneys--Diseases--Treatment
Abstract
Sevelamer (se-VEL-a-mer) is a medicine used to treat high levels of phosphorus (a mineral that builds strong bones and teeth) in the body. People with kidney disease are less able to remove phosphorus from their body. When phosphorus levels in the blood get too high, it pushes calcium out from your bones. Hemodialysis can remove some of the extra phosphorus, but medicines such as sevelamer are often needed to help remove more. How to take sevelamer and what side effects to watch for are reviewed. Renagel® is a brand name for sevelamer.
Notes
Previous title: Renagel (Sevelamer) and Hemodialysis
Responsibility
Prepared by: NSHA Renal Program
Pamphlet Number
1464
Less detail

Taking your medicines when you are sick: a guide for patients with chronic kidney disease (CKD)

https://libcat.nshealth.ca/en/permalink/chpams36519
Nova Scotia Health Authority. NSHA Renal Program. Halifax, NS: Nova Scotia Health Authority , 2019.
Pamphlet Number
1340
Available Online
View Pamphlet
This pamphlet lists medications to avoid when you are sick while managing chronic kidney disease. The pamphlet includes instructions for what to do if you are throwing up or have diarrhea, what to do if you are diabetic, as well as what to do if you are unsure whether to take a certain medication. It also gives a page for writing a sick day plan.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. NSHA Renal Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2019
Format
Pamphlet
Language
English
Physical Description
1 electronic document (5 p.) : digital, PDF file
Subjects (MeSH)
Kidney Diseases - drug therapy
Renal Insufficiency, Chronic - drug therapy
Subjects (LCSH)
Chronic renal failure
Kidneys--Diseases
Abstract
This pamphlet lists medications to avoid when you are sick while managing chronic kidney disease. The pamphlet includes instructions for what to do if you are throwing up or have diarrhea, what to do if you are diabetic, as well as what to do if you are unsure whether to take a certain medication. It also gives a page for writing a sick day plan.
Notes
Previous title: Taking your Medicines when you are Ill - A Guide for Patients with Chronic Kidney Disease
Responsibility
Prepared by: NSHA Renal Program
Pamphlet Number
1340
Less detail

14 records – page 1 of 1.